Clinical and Translational Oncology

, Volume 15, Issue 2, pp 87–94

MYC oncogene in myeloid neoplasias

Authors

  • M. Dolores Delgado
    • Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de MedicinaInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN
  • Marta Albajar
    • Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de MedicinaInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN
    • Servicio de HematologíaHospital Universitario Marqués de Valdecilla, and IFIMAV
  • M. Teresa Gomez-Casares
    • Servicio de Hematología and Unidad de InvestigaciónHospital Dr. Negrín
  • Ana Batlle
    • Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de MedicinaInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN
    • Servicio de HematologíaHospital Universitario Marqués de Valdecilla, and IFIMAV
    • Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de MedicinaInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN
Educational Series – Blue Series ADVANCES IN TRANSLATIONAL ONCOLOGY

DOI: 10.1007/s12094-012-0926-8

Cite this article as:
Delgado, M.D., Albajar, M., Gomez-Casares, M.T. et al. Clin Transl Oncol (2013) 15: 87. doi:10.1007/s12094-012-0926-8

Abstract

MYC is a transcription factor that regulates many critical genes for cell proliferation, differentiation, and biomass accumulation. MYC is one of the most prevalent oncogenes found to be altered in human cancer, being deregulated in about 50 % of tumors. Although MYC deregulation has been more frequently associated to lymphoma and lymphoblastic leukemia than to myeloid malignancies, a body of evidence has been gathered showing that MYC plays a relevant role in malignancies derived from the myeloid compartment. The myeloid leukemogenic activity of MYC has been demonstrated in different murine models. Not surprisingly, MYC has been found to be amplified or/and deregulated in the three major types of myeloid neoplasms: acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, including chronic myeloid leukemia. Here, we review the recent literature describing the involvement of MYC in myeloid tumors.

Keywords

MYCMyeloid neoplasiaAcute myeloid leukemiaChronic myeloid leukemiaMyelodysplastic syndromes

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012